Sanofi and Regeneron’s Dupixent becomes first biologic for kids under 12 with CSU

AI Briefing

• – Dupixent becomes first biologic for kids under 12 with CSU, FDA approves treatment for 2-11 year olds with uncontrolled chronic spontaneous urticaria.
• – Dupixent received FDA approval for a new indication in children under 12 with uncontrolled CSU.
• – Sanofi and Regeneron's Dupixent gets FDA approval for pediatric use in children with uncontrolled CSU.